Browse
Submit Data
Databases
API
Help

Dataset Information

9 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Clinical trial of human Solid Tumor Multi-gene Mutation Combined Detection Kit (High-throughput sequencing)

ABSTRACT: Interventions: Gold Standard:Reference methods: 1. Total exome sequencing (WES) 2. Multiple fluorescence PCR capillary electrophoresis (PCR-STR); Comparison method: comparison of similar kits;Index test:Information of reagents to be examined: (1) Product name: Human solid Tumor Multi-gene Mutation Combined Detection Kit (high-throughput sequencing method); (2) Packing specification: 48 test/box; (3) Storage conditions: Kit 1 was stored at -25~-15?, Kit 2 at -85~-70?, Kit 3 at 2-8 ?, kit 4 at 10-30 ?; (4)&# Primary outcome(s): Non-small cell lung cancer/colorectal cancer/gastrointestinal stromal tumor/stomach cancer/glioma/thyroid cancer/breast cancer/ovarian cancer/melanoma/cholangiocarcinoma/urothelial carcinoma/prostate cancer/other malignant solid tumor genes Study Design: Sequential

DISEASE(S): Non-small Cell Lung Cancer/colorectal Cancer/gastrointestinal Stromal Tumor/stomach Cancer/glioma/thyroid Cancer/breast Cancer/ovarian Cancer/melanoma/cholangiocarcinoma/urothelial Carcinoma/prostate

PROVIDER: 36510 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

The combination human 13 gene mutation Detection kit (reversible terminal termination sequencing) complements the clinical trial

Project description:Interventions: Gold Standard:Comparison methods :(1) comparison of similar kits;(2) Sequencing method;Index test:Human 13 gene mutation Combination Detection Kit (reversible terminal termination sequencing method) Primary outcome(s): Lung and gastrointestinal tumor genes Study Design: Sequential

| 2696826 | ecrin-mdr-crc

Human 13 gene mutation analysis software complements clinical trials

Project description:Interventions: Gold Standard:Comparison methods : 1. comparison of similar kits; 2. Sequencing method.;Index test:Product name: Human 13 gene mutation analysis software; Manufacturer: Guangzhou Flancite Medical Laboratory Co., LTD. Model: BRTMAS - 1 Primary outcome(s): Lung and gastrointestinal tumor genes;Positive coincidence rate, negative coincidence rate and total coincidence rate;consistency Study Design: Factorial

| 2696279 | ecrin-mdr-crc

Detection kit of the combination of methylated SDC2 and TFPI2 (fluorescence PCR method)

Project description:Interventions: Gold Standard:The double-blinded clinical trial was conducted to simultaneously assessing the kit with colonoscopy and/or pathological examinations for the detection of colorectal cancer. The overall coincidence rate of the kit in clinical practice was then calculated according to the results of statistical analysis.;Index test:Detection kit of the combination of methylated SDC2 and TFPI2 (fluorescence PCR method)(Product Name: iColocomf?) Primary outcome(s): Sensitivity;Specificity;Accuracy;Kappa Study Design: Sequential

| 2726190 | ecrin-mdr-crc

Clinical trial of Human BRAF Gene V600E Mutation Diagnostic kit (Fluorescence PCR Analysis)

Project description:Interventions: Gold Standard:Fluorescence PCR Analysis;Index test:Human BRAF Gene V600E Mutation Diagnostic kit (Fluorescence PCR Analysis) Primary outcome(s): colorectal cancer;cancerous goiter Study Design: Diagnostic test for accuracy

| 2676654 | ecrin-mdr-crc

Multi-center Clinical Trial of Methylation Detection Kit for SDC2 Gene (Real Time PCR) (Product Name: ColoSafe)

Project description:Interventions: Gold Standard:colonoscopy, Pathological examination;Index test:Methylation Detection Kit for SDC2 Gene (Real Time PCR)(Product Name: ColoSafe) Primary outcome(s): Sensitivity;Specificity;ACC;Kappa Study Design: Sequential

| 2687377 | ecrin-mdr-crc

Isolation of Circulating Tumor Cells from Small Cell Lung Cancer patients using CD56+ as a marker

Project description:We have isolated Circulating Tumor Cells from four Small Cell Lung Cancer Patients at diagnosis and relapse using a two-step method developed in the laboratory. Subsequently, Whole-Exome sequencing was performed on these samples as well as on the corresponding biopsies.

2023-01-11 | E-MTAB-10766 | biostudies-arrayexpress

Whole-exome sequencing (WES) of single glands from opposite side of two colorectal tumors and WES of colorectal cancer xenografts derived from single cell culture to study tumor growth dynamics

Project description:Single Gland Whole-exome sequencing: building on our prior description of multi-region WES of colorectal tumors and targeted single gland sequencing (E-MTAB-2247), we performed WES of multiple single glands from different sides (right: A and left: B) of two tumors in this study (tumor O and U) on the illumina platform using the Agilent SureSelect 2.0 or illumina Nextera Rapid Capture Exome kit (SureSelect or NRCE, as indicated in the naming of fastq files). Colorectal Cancer Xenograft Whole-exome sequencing: The HCT116 and LoVo Mismatch-Repair-deficient colorectal adenocarcinoma cell lines were obtained from the ATCC and cultured under standard conditions. For both cell lines, a single âfoundingâ cell was cloned and expanded in vitro to ~6M cells. Two aliquots of ~1M cells were subcutaneously injected into opposite flanks (right and left) of a nude mouse and tumors allowed to reach a size of ~1B cells (1cm3) before the animal was sacrificed. Tumor tissue was collected separately from the right and left lesions and DNA was extracted for WES using the illumina TruSeq Exome kit or Nextera Rapid Capture Exome expanded Kits (Truseq or NRCEe), as was DNA from the first passage population (a polyclonal tissue culture for HCT116 and a polyclonal xenograft sample for LoVo), which were employed as a control to study mutation accumulation in culture and post xenotransplantation.

2017-05-01 | E-MTAB-5547 | biostudies-arrayexpress

Retrotransposition in Colorectal Cancer

Project description:<p>The purpose of this study is to ascertain the locations of somatic LINE-1 retrotransposition events in human colon tumor samples by pooling multiple tumor samples from different patients and performing a targeted resequencing assay (Ewing and Kazazian, Genome Research 2010) to sequence the 3' flanking regions of all insertions in the pooled sample. The result is compared to the result of applying the same method to pooled normal samples from the same patients as were used in the pooled tumor sample and selecting sites that show an insertion in the tumor but not in the normaltissue and do not correspond to any known non-reference LINE-1 insertion allele. The selected sites are then validated by site-specific PCR and capillary sequencing to confirm that they represent LINE-1 insertions and to obtain breakpoint sequences.</p>

| phs000536 | dbGaP

A multi-center study: the application value of plasma exosomal non-coding RNA in the early screening and clinical progress of colorectal cancer

Project description:Interventions: Gold Standard:Gastroscopy, colonoscopy, pathological diagnosis;Index test:Plasma exosome extraction: commercial plasma exosome extraction kit (EZB company) extraction. Extraction of plasma exosomal miRNA: Advanced probe method RT-qPCR extraction kit (Thermo Company). Primary outcome(s): exosome microRNA Study Design: Cohort study

| 40619 | ecrin-mdr-crc

Exome-capture RNAseq of microdissected FFPE human breast cancer cells, cancer-associated fibroblasts, and surrounding tumor-infiltrating lymphocytes

Project description:Here we describe the development of a robust method for RNA extraction and exome-capture RNA-sequencing of laser-capture microdissected (LCM) tumor cells (TC) and stromal immune cells (TIL) based on their morphology. We applied this method on seven tumor specimens and microbiopsies of triple-negative breast cancers (TNBC) stored in FFPE blocks. Together, we showed that combining LCM and RNA-sequencing on archived FFPE blocks is feasible and allows spatial transcriptional characterization of the tumor microenvironment.

2021-10-31 | E-MTAB-8760 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data